Posted by Michael Wonder on 02 Mar 2023
Affordable treatment for recurrent melanoma
2 March 2023 - From 1 March 2023, Australians with recurrent melanoma will have a new treatment option subsidised by the Pharmaceutical Benefits Scheme.
The PBS listings of Opdivo (nivolumab) and Yervoy (ipilimumab) will be expanded to be used in combination to treat Stage III or IV malignant melanoma in patients who experience a recurrence of melanoma while receiving or within 6 months of completing adjuvant PD-1 inhibitor monotherapy.
